FUJIFILM Announces Completion of 100th Program Using Protein Expression System
PTSM: Pharmaceutical Technology Sourcing and Management
The company announced that it has completed its 100th program using the pAVEway protein expression system, which was originally introduced to the market in 2007.
On June 20, 2017, FUJIFILM Diosynth Biotechnologies announced the completion of its 100th program using pAVEway Advanced Protein Expression system. The expression system was originally introduced to the market during the 2007 BIO International Convention in Boston, Massachusetts.
pAVEway was developed by FUJIFILM Diosynth Biotechnologies to enable the reliable and scalable GMP manufacturing of E.coli -based processes. The pAVEway system has the ability to control protein expression by allowing expression and secretion to be coupled. It also allows for slower expression, which can result in a higher chance of folding, and to sustain accumulation for many hours with continued cell growth. The system is suited to investigate difficult-to-express proteins with protein toxicity to the cells.
Source: FUJIFILM
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
